Agios Pharmaceuticals (AGIO) Reports Q3 2024 Earnings Call Details
Agios Pharmaceuticals (AGIO) reported Q3 2024 earnings call details, highlighting $1.7 billion in cash and investments, driven by FDA approval of vorasidenib. PYRUKYND (mitapivat) net revenue rose 22% year-over-year to $9 million, with positive clinical trial data and regulatory progress for thalassemia and sickle cell disease.
Tickers: $AGIO
Topics: clinical trials drug development FDA approval revenue growth sickle cell disease thalassemia